Monopar Therapeutics Inc. Shareholders' Equity
Monopar Therapeutics Inc. (MNPR) had Shareholders' Equity of $130.85 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-12
- 2026-06-30: Stockholders' Equity Attributable to Parent $130.85M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $135.39M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $137.83M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $141.56M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $130.85M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $135.39M 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $137.83M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $141.56M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $52.20M 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $53.59M 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $55.04M 10-Q · filed 2026-08-12 | |
| 2024-09-30 | $4.95M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $6.09M 10-Q · filed 2025-11-13 | $6.09M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $7.48M 10-Q · filed 2025-11-13 | $7.48M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $5.59M 10-K · filed 2026-03-27 | |
| 2023-09-30 | $6.61M 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $7.84M 10-Q · filed 2024-11-08 | |
| 2023-03-31 | $8.94M 10-Q · filed 2024-11-08 | |
| 2022-12-31 | $10.09M 10-K · filed 2025-03-31 | |
| 2022-09-30 | $12.51M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $14.52M 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $16.97M 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $18.94M 10-K · filed 2024-03-28 | |
| 2021-09-30 | $21.28M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $23.35M 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $25.10M 10-Q · filed 2022-11-10 | |
| 2020-12-31 | $15.69M 10-K · filed 2023-03-23 | |
| 2020-09-30 | $17.49M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $12.15M 10-Q · filed 2021-11-12 | |
| 2020-03-31 | $12.40M 10-Q · filed 2021-11-12 | |
| 2019-12-31 | $12.63M 10-K · filed 2022-03-24 | |
| 2019-09-30 | $4.62M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $5.13M 10-Q · filed 2020-11-12 | |
| 2019-03-31 | $5.77M 10-Q · filed 2020-11-12 | |
| 2018-12-31 | $6.92M 10-K · filed 2021-03-25 | |
| 2018-09-30 | $7.58M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $8.12M 10-Q · filed 2019-11-12 | |
| 2018-03-31 | $8.86M 10-Q · filed 2019-11-12 | |
| 2017-12-31 | $9.62M 10-K · filed 2020-03-27 | |
| 2016-12-31 | $2.83M 10-K · filed 2019-02-26 | |
| 2015-12-31 | $2.75M 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |